Accuray Inc

Accuray Inc has a market capitalization of $33.83 million and a price-to-book ratio of 0.42, indicating a significant discount to its book value. The company's liquidity position is characterized by $57.42 million in cash and equivalents, but this is offset by $136.52 million in long-term debt, resulting in a debt-to-equity ratio of 1.68. The current ratio of 1.65 suggests the company has sufficient short-term assets to cover its short-term liabilities, but the overall capital structure is heavily leveraged. Profitability metrics show a mixed picture. The company reported a net loss of $1.59 million and an operating income of $9.31 million, translating to a return on equity of -1.96% and a return on assets of -0.34%. These figures are below the industry median for return on equity and return on assets, which are typically positive for firms in the healthcare equipment sector. The gross profit margin of 32.06% is relatively strong, but the net loss indicates inefficiencies in operating expenses or other cost structures. Geographically, Accuray's revenue is not disclosed by region, but the company's primary market is the United States, with a significant presence in international markets. The lack of detailed geographic breakdown limits the ability to assess regional risk exposure. The company's revenue concentration is not explicitly stated, but the absence of segment-specific data suggests a relatively undiversified business model. Looking ahead, the company's growth trajectory is uncertain. The current fiscal year is expected to show a modest increase in revenue, but the next fiscal year's outlook is not provided. The company's operating cash flow of $2.86 million and free cash flow of $287,000 are positive signs, but they are insufficient to cover the net loss. The capital expenditure of -$4.27 million indicates a reduction in investment, which may signal a strategic shift or financial constraints. Risk factors include a medium liquidity risk due to the company's high debt levels and a net cash position that is negative after subtracting total debt. The dilution risk is assessed as low, but the company's financial leverage and net loss could impact its ability to raise additional capital without diluting existing shareholders. The risk assessment also highlights the need for careful monitoring of the company's debt management and cash flow generation. Recent events include analyst estimates that suggest a mean price target of $2.52, with a median price target of $2.52 and a strong buy recommendation from two analysts. These estimates indicate a positive sentiment among analysts, but the company's current financial performance does not fully support such optimism. The lack of recent filings or transcripts limits the ability to assess the company's strategic direction and operational performance in detail.